GHK-Cu, Melanotan II and GLOW compared
The word colour can describe a substance, a tissue response or an impression. Putting the actual observation beside the claim changes this comparison.
Colour and the measured outcome
| GHK-Cu | Melanotan II | GLOW blend | |
|---|---|---|---|
| Colour in the discussion | Blue copper complex; separate questions about skin tone | Melanin produced after melanocortin signalling | “Glow” as an appearance claim |
| Human observation to examine | Small topical studies reviewed for skin appearance; a 45-man trial of a GHK combination for hair count | Gum and cheek pigmentation in a case report; a 10-man erectile-function study | Constituent research reviewed, with scarce rigorous human safety data |
| Main limitation | Formulation and route matter; small human trials | Case reports give no usual risk rate; no completed Phase II or III trials | No controlled trial of the combination |
| Status | Legal cosmetic ingredient as topical Copper Tripeptide-1; no approved drug indication | No approved use anywhere | No approved combination product |
| Tested sport | Not itemised in the lists covered by the source record; S0 may apply | Prohibited under S0 | Prohibited through BPC-157 and TB-500 |
I give the middle row the most space because these observations answer markedly different questions. An increase in hair count cannot establish even pigmentation. A mouth-pigment case cannot tell us how frequently that change occurs. The blend still lacks its own measured result.
Cosmetic ingredients and medicines
Copper Tripeptide-1 has an INCI name, the naming system used for cosmetic ingredients, and permitted topical cosmetic use in the US, UK and EU. US cosmetics do not undergo the drug pre-approval process. An ingredient name therefore describes a place in cosmetic formulation; it supplies no approved medical indication or established systemic safety for GHK-Cu.
Melanotan II has a separate source of confusion: approved relatives. Afamelanotide and bremelanotide have their own indications and clinical evidence. The melanocortin history traces their family relationship, while the present regulatory record distinguishes their approvals from Melanotan II's unapproved status.
The review of unapproved peptide therapies is useful for GLOW precisely because it names the constituents and still describes scarce human safety evidence. I would not upgrade a mixture's standing because one ingredient has a familiar cosmetic name.
The next measurements
For topical GHK-Cu, I would value trials that name the exact preparation and distinguish pigment from wrinkles, texture and satisfaction. The existing delivery review makes clear how much formulation can change the experiment.
For Melanotan II, the mouth case leaves the frequency and full course of mucosal pigmentation unanswered. The unequal fading at follow-up is enough to make those concrete research questions. Serious adverse-event reports and absent approval already prevent a reassuring account of cosmetic use.
For GLOW, my first questions concern identity, stability and combined exposure. Only then could a controlled trial put a named outcome against a defined mixture. The BPC-157 review calls for well-designed clinical work even for a single constituent. Those are research priorities, with no personal-use instructions implied.